NCT02990221 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Andrews MD
Cryosurgery for common skin conditions. Am Fam Physician. 2004 May 15;69(10):2365-72. Review.
Cohen JL
Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010 Jun;3(6):39-44.
Fidler B, Goldberg T
Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. P T. 2014 Jan;39(1):40-6.
Frost CA, Green AC
Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct;131(4):455-64. Review.
Fu W, Cockerell CJ
The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol. 2003 Jan;139(1):66-70. Review.
Ortonne JP
From actinic keratosis to squamous cell carcinoma. Br J Dermatol. 2002 Apr;146 Suppl 61:20-3. Review.
Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R
Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010 Mar;146(3):288-93. doi: 10.1001/archdermatol.2009.37
Vatve M, Ortonne JP, Birch-Machin MA, Gupta G
Management of field change in actinic keratosis. Br J Dermatol. 2007 Dec;157 Suppl 2:21-4. Review.

A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy

Clinical trial NCT02990221 - References